JP2025508779A5 - - Google Patents

Info

Publication number
JP2025508779A5
JP2025508779A5 JP2024549466A JP2024549466A JP2025508779A5 JP 2025508779 A5 JP2025508779 A5 JP 2025508779A5 JP 2024549466 A JP2024549466 A JP 2024549466A JP 2024549466 A JP2024549466 A JP 2024549466A JP 2025508779 A5 JP2025508779 A5 JP 2025508779A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024549466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508779A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/078127 external-priority patent/WO2023160651A1/zh
Publication of JP2025508779A publication Critical patent/JP2025508779A/ja
Publication of JP2025508779A5 publication Critical patent/JP2025508779A5/ja
Pending legal-status Critical Current

Links

JP2024549466A 2022-02-24 2023-02-24 抗体及びその薬物コンジュゲート並びに用途 Pending JP2025508779A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202210172397 2022-02-24
CN202210172397.7 2022-02-24
CN202210916833.7 2022-08-01
CN202210916833 2022-08-01
CN202211183393 2022-09-27
CN202211183393.5 2022-09-27
PCT/CN2023/078127 WO2023160651A1 (zh) 2022-02-24 2023-02-24 一种抗体及其药物偶联物和用途

Publications (2)

Publication Number Publication Date
JP2025508779A JP2025508779A (ja) 2025-04-10
JP2025508779A5 true JP2025508779A5 (enExample) 2026-03-02

Family

ID=87764835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024549466A Pending JP2025508779A (ja) 2022-02-24 2023-02-24 抗体及びその薬物コンジュゲート並びに用途

Country Status (8)

Country Link
US (1) US20250333541A1 (enExample)
EP (1) EP4484446A1 (enExample)
JP (1) JP2025508779A (enExample)
KR (1) KR20240150773A (enExample)
CN (1) CN118786146A (enExample)
AU (1) AU2023225240A1 (enExample)
CA (1) CA3244292A1 (enExample)
WO (1) WO2023160651A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025185619A1 (zh) * 2024-03-04 2025-09-12 苏州宜联生物医药有限公司 抗体药物偶联物及其制备方法和用途
WO2025185559A1 (zh) * 2024-03-04 2025-09-12 杭州中美华东制药有限公司 抗FGFR2b抗体、其抗体药物偶联物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
BR112012031727B1 (pt) 2010-06-15 2022-03-29 Genmab A/S Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
CN111727075B (zh) * 2017-11-27 2024-04-05 普渡制药公司 靶向人组织因子的人源化抗体
BR112020020466A2 (pt) 2018-04-06 2021-01-12 Seattle Genetics, Inc. Conjugados de peptídeo de camptotecina
CN110575547B (zh) * 2018-06-07 2021-07-30 中国科学院上海药物研究所 靶向于tf的抗体-药物偶联物及其制法和用途
CR20220047A (es) * 2019-07-03 2022-06-23 Zymeworks Inc Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados
BR112023000455A2 (pt) * 2020-07-10 2023-03-28 Iconic Therapeutics Inc Tratamento de doença inflamatória que usa anticorpos de fator antitecidual
TWI888610B (zh) * 2020-07-27 2025-07-01 大陸商上海拓界生物醫藥科技有限公司 抗cd79b抗體藥物偶聯物、其製備方法及其醫藥用途
EP4257154A4 (en) 2021-02-09 2026-04-22 Medilink Therapeutics Suzhou Co Ltd CONJUGATED WITH A BIOACTIVE SUBSTANCE, ITS PREPARATION PROCESS AND ITS USE

Similar Documents

Publication Publication Date Title
JP2024535637A5 (enExample)
US20240409628A1 (en) Antibody, antibody-drug conjugate thereof and use thereof
JP6861777B2 (ja) 抗her2抗体−薬物コンジュゲート
TWI851552B (zh) 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物
JP2025138756A (ja) 抗her2抗体-薬物コンジュゲート
CA2946796C (en) Antibody-drug-conjugate and its use for the treatment of cancer
TWI826828B (zh) 抗her3抗體-藥物結合物及含有其之醫藥及醫藥組成物
ES2795818T3 (es) Anticuerpos CD48 y conjugados de los mismos
JP2025508009A5 (enExample)
CN117946277A (zh) 多特异性抗体及其制备和使用方法
JP2025508779A5 (enExample)
TW202417508A (zh) 抗trop2/egfr抗體及其用途
JP2025533983A (ja) リンカー-ペイロード化合物、複合体、及びその用途
KR20240150781A (ko) B7-h4 항체 약물 접합체를 포함하는 암 치료를 위한 병용요법
AU2022316425A1 (en) Drug conjugate of eribulin derivative
CN118873678A (zh) 抗体偶联药物及其用途
US20260021194A1 (en) Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
WO2024235135A1 (zh) 大环化合物及其制备方法和用途
WO2025227010A1 (en) Protein tyrosine kinase 7 antibodies and antibody-drug conjugates
RU2025101032A (ru) Слитый белок, содержащий антитело против cd73 и il-2, и его применение
WO2025106658A1 (en) 5t4 antibody drug conjugates and methods of their use
WO2025056748A1 (en) Antibody-drug conjugate
WO2024235131A1 (zh) 大环类药物偶联物及其制备方法和用途
CN118804928A (zh) 用于与pd-1x ctla-4双特异性分子组合使用b7-h3抗体-药物缀合物的方法
EA051050B1 (ru) Конъюгат лекарственного средства производного эрибулина